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Introduction
Globally people living with HIV (PLHIV) numbered 
around 36.7 million at the end of 2015 according to 
the latest United Nations Acquired Immune Deficiency 
Syndrome (UNAIDS) 2016 data covering 160 countries 
(Global AIDS Update 2016 | UNAIDS, 2016). The burden 
of the epidemic continues to vary considerably bet ween 
countries and regions. New HIV infections in the Mid­
dle East and North Africa (MENA) region have incre­
ased by 31% since 2001, which is the highest increase 
among all regions in the world (Gokengin et al., 2016).
In Egypt, the estimated number of PLHIV is around 
11,000 individuals (7,000–19,000) with overall low 
pre valence among the general population (< 0.02%). 
Greater Cairo and Alexandria; which have about one 
third of the population of the country, account for 
almost two thirds of all HIV infected patients detected. 
Egypt has a national epidemic concentrated in two key 
populations; people who inject drugs (PWID) and men 
who have sex with men (MSM) (Egypt National AIDS 
program NAP, 2015). Egyptian National guidelines on 
clinical care and antiretroviral therapy (ART) states that 
Care begins with CD4 cell count testing and those with 
CD4 count of 500 or lower are eligible for ART (National 
Guideline on Clinical Care and Antiretroviral Drugs for 
Treating and Preventing HIV Infection, Egypt, 2014).
HIV has a variable rate (spectrum) of progression in 
infected people. This variation in disease development is 
one parameter that led to the classification of patients as 
rapid progressors (RPs), slow/intermediate progressors, 
controllers; elite controllers (EC), viraemic controllers 
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Middle East and North Africa (MENA) new HIV cases show the highest increase among all regions in the world. Even though Egypt has 
a low prevalence among the general population (< 0.02%), a national HIV epidemic occurs in certain population risk groups. The current 
study was conducted to asses clinical and immunological disease progression; following up viral load (VL) and detecting delta­32 CCR5 
genotype polymorphism in selected cases, determining unemployment rate and identify predictors of employment for HIV­cases. A cross 
sectional design was adopted. HIV infected cases attending Alexandria Fever Hospital (AFH) for one year. Interview questionnaire and 
four CD+4 counts were done for all patients, HIV VL and delta­32 CCR5 polymorphism were done for selected cases. Sexual transmis­
sion and drug abuse are the most important risk factors. Infectious comorbidity increases the rate of HIV progression. CD4+ count at the 
end of the study; CD+4 (4), count was significantly higher than all other CD4+ readings among the whole cohort and among the treated 
group. Also, VL at the end of the study; VL(2), was significantly higher than VL(1) among the untreated group. Unemployment rate was 
40%. Male gender and obtaining vocational training were significant predictors of employment. It can be concluded that having a family 
member living with HIV and drug abusers are high risk groups for HIV acquisition. Factors responsible for progression of HIV should be 
further investigated. Antiretroviral therapy is very effective in checking HIV replication rate, delaying the progression of HIV, reconstitut­
ing the immune response and should be available for all cases detected.
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(VC) and long­term nonprogressors (LTNPs). The clas­
sification is also based on CD4 count, HIV viral load 
(VL), and ART. Different studies suggested different 
definitions to these subgroups (Gurdasani et al., 2014).
Understanding mechanisms for significantly delay­
ing disease progression remains a worthwhile research 
goal. Nonprogression probably results from multiple 
virol ogic, immunologic, and genetic factors. In terms of 
host genetics, some LTNPs display polymorphisms in 
chemo kine receptors (CCR5 and CXCR4) and chemo­ 
kines (e.g. MIP­1α and RANTES). Nearly 11% of Cauca­
sians and 2% of Blacks are homozygous for the CCR5­
delta32 mutation (Poropatich and Sullivan, 2011).
Employment status is a major predictor of health 
status and living conditions. However, unemployment 
rate among HIV – cases ranges from 45% to 65%. It is 
still higher compared with the general population, in 
many countries including highincome ones (Legarth 
et al., 2014). Women, younger age, poor educational 
level, progressed HIV infections, or Hepatitis C virus 
(HCV) co­infection are risk factors for unemployment 
among HIV­cases (Gros et al., 2016).
Our study aimed at (1) assessing clinical and immu­
nological disease progression; (2) evaluating and fol­
lowing up the VL of selected cases, (3) detecting delta­
32 CCR5 genotype polymorphism in selected cases, (4) 
determining unemployment rate and identify predic­
tors of employment for HIV­cases.
Experimental
Material and Methods
A cross sectional design was adopted. All HIV 
infected cases attending Alexandria Fever Hospital 
(AFH) during field work period of the study from Janu­
ary to December 2015, who agreed to participate in the 
study were included (n = 150). Patients were excluded 
if they were younger than 18 years or refused to par­
ticipate. They were diagnosed earlier by AFH protocol 
for HIV diagnosis (National Guideline on Clinical Care 
and Antiretroviral Drugs for Treating and Preventing 
HIV Infection, Egypt, 2014).
Study tools. An interview questionnaire. A pre­
designed questionnaire was used to obtain data from 
all HIV infected patients (n = 150) concerning a) socio­
demography, b) risk factors, c) health status, d) his­
tory of the disease and e) treatment regimens of the 
participants.
Laboratory investigations
Blood samples were collected and analyzed at the 
AFH and Alexandria Faculty of Medicine (AFM) Cen­
tral Laboratories.
The immunological status of the participants 
(CD4 count). CD4 + T­cell count (cells/mm3) was 
taken as an immunological marker in the course of 
disease progression. Five CD4 counts were performed 
for all patients (n = 150): CD4+ (0); earliest CD4+ 
T­cell count (on diagnosis of HIV), CD4+ (1); CD4+ 
measured at the beginning of the study, CD4+(2); 
CD4+ measured after 3 months of the study, CD4+(3); 
CD4+ measured after 6 months of the study, CD4+(4); 
CD4+ measured after 9 months of the study.
Whole blood (200 μl) was collected in EDTA vacu­
tainer tubes (Becton­Dickinson Mt View, California,). 
The PartecCyFlow Counter® (Partec GmbH, Munster, 
Germany) for CD4+ T­cell enumeration was used for 
performing the CD4 count. The Partec CD4% Reagent 
kit consists of MEM­24; a monoclonal antibody, which 
recognizes human CD4 antigen (Manasa et al., 2007). 
HIV viral load. VL was done twice to selected cases 
(n = 20). First VL (VL1) was done at the beginning of the 
study and the second VL (VL2) was done after one year. 
In our study we were more puzzled by PLHIV not show­
ing any sign or symptoms for variable duration of time 
despite of not receiving treatment. So, we choose 16 out 
of the 29 untreated cases in our cohort to be followed 
up according to their VL in conjunction with their CD4 
count. The other 13 untreated cases were excluded for 
the following reasons, presence of co­morbid infective 
diseases (HBV/HCV), noncompliance, and unwilling­
ness to participate. In scope of covering the whole spec­
trum of different patterns of progression, 4 treated inter­
esting cases were also chosen. A case with CD4 rapid 
decline after HIV diagnosis that dramatically improved 
on ART. The parents; diagnosed 17 years ago, of a family 
with four children, all are PLHIV. Lastly a case diag­
nosed and untreated for 5  years ago then underwent 
treatment when its CD4 started to decline.
Plasma were separated from the blood samples 
within 4  hours of collection and stored in a −20°C 
freezer. RNA extraction was performed using Qiagen 
QIAamp viral RNA mini spin protocol according to 
manufacturer instructions.
The VL for each of these samples was determined 
using a US FDA­approved kit (Artus HIV­1 RG RT­
PCR kit; Qiagen, Germany).
As described by Luft, 2011; primers were diluted to 
a stock concentration of 200 mM and stored at −20°C. 
A concentration of 2 mM for SYBR Green­based reac­
tions was done. A final primer concentration of 10 pico­ 
moles/ul was able to provide high­quality and con si­
stent results. 
Gene specific primers for the most conserved region 
of HIV­1 gag gene were chosen (Genbank)
Forward: 5’­ACATCAAGCAGCCATGCAAAT­3’,
Reverse: 5’­TACTAGTAGTTCCTGCTATGTC­3’.
Biosystems StepOneTM Real Time PCR system was used 
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with the following conditions: one cycle of reverse tran­
scription at 45°C for 30 min, followed by one cycle of 
polymerase activation at 95°C for 5 min then 40 cycles 
of PCR amplification. Each cycle consisted of denatura­
tion at 95°C for 15 s, annealing at 55°C for 15 s, and 
extension at 72°C for 30 s.
CCR5 genotyping. Eight cases that fulfilled the 
criteria of being LTNPs (according to CD4 count, VL, 
duration since diagnosis and never on ART) were cho­
sen for genotyping for the CCR5­delta32­allele.
After the genomic DNA was extracted using QIA­
GEN­Blood­Midi­Kit (Qiagen, Germany), screening of 
the cases for the CCR5­delta32­allele was performed 
with a genomic PCR using primers flanking the site of 
the deletion (forward: 5’­CTCCCAGGAATCATCTTTA 
C­3’, reverse: 5’­TCATTTCGACACCGAAGCAG­3’). 
The PCRs were performed in 50­μl volumes, each com­
prising 2 × mixture containing 1.5 mM MgCl2, 10 mM 
dNTPS, 2.5 U Taq DNA polymerase, 50 ng genomic 
DNA, and 20 µmol of each primer (Gero, 2011). 
The amplification conditions were as follows: dena­
turation at 94°C for 1 min, followed by 35 cycles of PCR 
amplification. Each cycle consisted of denaturation at 
94°C for 30 s, annealing at 58°C for 30 s, and extension 
at 72°C for 30 s. Following the 35 cycles of PCR there 
was an extension for 10 min at 72°C. 
Results were confirmed by direct sequencing using 
the BigDye® ­ Terminator ­ 1.1. ­ Cycle­Sequencing ­ Kit 
(Applied Biosystems, Germany).
Statistical analysis of the data. The collected data 
were coded and typed onto computer files. All analy­
ses were performed using SPSS/Pc + software program 
version 20.0 (Kirkpatrick and Feeny, 2013). The level 
of significance selected for results was 5% (α = 0.05). 
Analytic statistics were carried out using Chi­Square 
test (X2), Fisher’s exact test and Student t­test were used 
to reveal association between characteristics of HIV­
infected patients and HIV progression.
Wilcoxon Signed Ranks test, Paired t­test were done 
to compare mean values of HIV immunological and 
virological markers reported at different points of time. 
Additionally, unemployment rate was calculated. Uni­
variate analysis was conducted where basic sociodemo­
graphic and health status characteristics were examined 
for association with respect to employment status, using 
Chi­Square test (X2), Fisher’s exact test, and Monte 
Carlo test for categorical variables, and Student t­test 
for quantitative variables. All variables that were signifi­
cantly associated with employment status in univariate 
analysis, were included in multivariate analysis using 
logistic regression model to investigate predictors of 
employment among the studied HIV­cases.
Ethical clearance. The protocol of the current 
study was approved by AFH, MOH and the Medical 
Research Ethics Committee at AFM. Objectives of the 
study, expected benefits, types of information to be 
obtained, procedures, and publication were explained 
to each participant and an informed written consent 
was obtained before participation in the study. Moreo­
ver, confidentiality of data was insured.
Results
Characteristics of the studied HIV-infected 
patients with respect to disease progression (n = 150). 
Two thirds of our study HIV infected patients were males 
(n = 100, 66.7%). Their age ranged from 18–62  years 
with mean age of (33.93 ± 9.25) years. The majority 
of our patients have urban residence (n = 142, 94.7%) 
with 46 of them (30.7%) clustered in Amryia district. As 
regarding HIV acquisition risk factors, family member 
living with HIV was present in 55.3% of cases (n = 83), 
of which 67.46% (n = 46) have a spouse having HIV. 
Addiction was found in about 29.3% (n = 44) while 24% 
(n = 36) were intravenous (IV) abusers. 
Regarding HIV progression, based on CD4 count, 
duration since diagnosis and ART, RP accounted for 
56% of the studied group followed by progressors, con­
trollers and LTNP accounting for 24.7%, 12.7% and 
6.7% respectively. Among the studied group 24.6% 
(n = 37) had infectious comorbidity (Hepatitis B and 
HCV). In the treated group (80%, n = 121), Truvada + 
Efavirnez was the treatment regimen in 71.1% of cases 
and Efavirnez + Zidavudine + Lamivudine in 28.9% in 
cases with comorbidity.
Among different parameters, the presence of comor­
bidity was significantly associated with disease progres­
sion (X2 = 6.61; p = 0.01) (Table I).
Immunological makers; CD4 + T-cell count (cells/
mm3) among the studied HIV-infected patients. 
CD4 + (4) was significantly higher than the other four 
readings [(CD4 + (0), CD4 + (1) CD4 + (2), CD4 + (3)] 
among all HIV infected patients; n = 150, and also 
among the treated group; n = 121, (p = 0.00 and p = 0.00 
respectively) (Table II).
Viral Load – VL (IU/ml) among the studied HIV-
infected patients. VL was taken as a virological marker 
in the course of disease progression. Twenty cases that 
were chosen, showing different patterns of progression; 
one was RP, three intermediate were progressors, eight 
were controllers, 8 were LTNPs. Two LTNPs cases had 
VL BDL (< 50 IU/ml). VL(2) was significantly higher 
than VL(1) when assessing patients with detectable 
VL; n = 18, and also when assessing untreated patients 
with detectable VL; n = 14, (p = 0.00 and p = 0.00 respec­
tively) (Table III).
CCR5 genotyping. PCR fragment of 200 base pairs 
(bp) were detected for CCR5 gene. The eight LTNP selec­ 
 ted cases were found to carry the wild type of CCR5.
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Characteristics of the studied HIV-infected 
patients with respect to patients’ employment status 
(n = 150). Unemployment rate among HIV­infected 
pat ients was 40%. Most of employed HIV­infected 
patients were men (85.6%), while most of unemployed 
group were women (61.7%) (X2 = 36.12; p = 0.00). Addi­
Gender 
Male 19 (65.5%) 81 (66.9%) 
X2 = 0.02 (0.88)
Female  10 (34.5%) 40 (33.1%)
Age (Years) (Mean ± SD) 33.97 ± 11.06 33.93 ± 8.81 t = 0.02 (0.98)
Residence
Rural 2 (6.9%) 6  (5%) FEP = 0.65
Urban 27 (93.1%) 115 (95%)
History of blood transfusion 4 (13.8%) 13 (10.7%) FEP = 0.74
Family member living with HIV 14 (48.3%) 69 (57%) X2 = 0.72 (0.39) 
IV drug abuser 6 (20.7%) 30 (24.8%) X2 = 0.21 (0.64) 
Employment status
Unemployed 12 (41.4%) 48 (39.7%) 
X2 = 0.02 (0.86)
Employed 17 (58.6%) 73 (60.3%)
Co-morbidity
None 26 (89.7%) 79 (65.3%) 
X2= 6.61 (0.01)*
Infectious< and/or non­infectious# 3 (10.3%) 42 (34.7%)
Table I
Characteristics of the studied HIV­infected patients with respect to disease progression (n = 150)
Abbreviations: HIV – human immune deficiency virus; IV – intravenous; # – diabetes Mellitus, hypertension;
< – hepatitis C virus, hepatitis B virus; $ – includes long­term non­progressive and controller;
^ – includes progressive and rapidly progressive; X2: Chi square test; FE: Fisher’s Exact test; t: student t test;





(n = 121) Test of significance
(P value)
No. (%) No. (%)
Table II
Immunological makers; CD4 + T­cell count (cells/mm3) among
the studied HIV­infected patients
CD4 + T­cell count among all HIV­infected patients (n = 150)
Min­Max Mean ± SD Test of significance(p­value)
CD4+ (0) 28 – 1555 438.35 ± 259.15 Z” = –8.66 (0.00)**
CD4+ (1) 28 – 1555 474.14 ± 294.32 Z$ = –8.11 (0.00)**
CD4+ (2) 48 – 1560 484.50 ± 283.11 Z^ = –8.48 (0.00)**
CD4+ (3) 67 – 1500 495.72 ± 279.55 Z@ = –7.95 (0.00)**
CD4+ (4) 74 – 1523 506.45 ± 279.21
CD4 + T­cell count among HIV­infected patients
who received treatment (n = 121)
Min­Max Mean ± SD Test of significance(p­value)
CD4+ (0) 28 – 732 360.60 ± 166.30 t” = –7.61 (0.00)**
CD4+ (1) 28 – 815 367.09 ± 170.26  t$ = –10.06 (0.00)**
CD4+ (2) 48 – 820 382.83 ± 166.35 t^ = –7.91 (0.00)**
CD4+ (3) 67 – 859 397.23 ± 168.15 t@ = –5.46 (0.00)**




HIV – human immune deficiency virus;
Z – Z value of Wilcoxon Signed Ranks test; t: paired t­test; 
D: standard deviation; ** – significant at p ≤ 0.01 (2­tailed);
” – CD4+ (0) – CD4+ (4); $ – CD4 + (1) – CD4 + (4);
^ – CD4 + (2) – CD4 + (4); @ – CD4 + (3) – CD4 + (4);
CD4 + (0) – earliest CD4 + count;
CD4 + (1) – CD4 + measured at the beginning of the study;
CD4 + (2) – CD4 + measured after 3 months of the study;
CD4 + (3) – CD4 + measured after 6 months of the study;
CD4 + (4) – CD4 + measured after 9 months of the study
CD4 + T­cell count among HIV­infected patients
who did not receive treatment (n = 29)
Min­Max Mean ± SD Test of significance(p­value)
CD4 + (0) 369 – 1555 762.72 ± 322.13  Z” = –1.82 (0.06)
CD4 + (1) 369 – 1555 920.79 ± 283.90  t$ = 0.02 (0.97)
CD4 + (2) 412 – 1560 908.72 ± 277.28 t^ = –0.58 (0.56)
CD4 + (3) 481 – 1500 906.65 ± 279.10 t@ = –1.12 (0.27)
CD4 + (4) 521 – 1523 920.27 ± 278.25
tionally, 41.1% and 6.7% of employed HIV­infected 
patients obtained vocational training and secondary 
school education respectively, compared with unem­
ployed group (11.7% and 5% respectively) (Monte Carlo p = 
= 0.00). Significantly higher percentage of unemployed 
HIV­infected patients had family member living with 
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HIV (68.3%) compared with employed group (46.7%) 
(X2 = 6.83; p = 0.00). Moreover, 34.4% of employed 
HIV­infected patients were PWID compared with 8.3% 
of unemployed group (X2 = 13.45; p = 0.00). According 
to HIV progression, 17.8%, 63.3%, 4.4%, and 14.4% of 
employed HIV­infected patients had progressive, RP, 
LTNP, and controllers respectively, compared with 
unemployed patients (35%, 45%, 10% and 10%, respec­
tively), (Monte Carlo p = 0.03) (Table IV).
Predictors of employment in the studied HIV-
infected patients (n = 150) (Table V). Characteris­
tics that were significantly associated with respect to 
employment status in univariate analysis were included 
in multivariate analysis using logistic regression model. 
The overall model was significant (model X2 = 57.11, 
p = 0.00); significant predictors of employment were 
male gender (odds ratio [OR]: 7.29; 95% confidence 
interval [CI]: 2.72–19.52), and obtaining vocational 
training (OR: 6.04; 95%CI: 1.81–20.16). According to 
the results, HIV­infected man was 7.3 times more likely 
to be employed compared with HIV­infected woman. 
Moreover, HIV­infected patient who obtained voca­
tional training was 6 times more likely to be employed 
than an illiterate HIV­infected patient. Although, in 
univariate analysis, having a family member living 
with HIV, PWID and HIV progression was significantly 
associated with employment; yet, these associations 
were no longer significant after adjustment for other 
covariates in multivariate analysis (Table V).
Discussion
The world has committed to ending the AIDS 
epidemic by 2030 as declared by UNAIDS 2016. The 
90­90­90  target provides that by 2020: (a) 90% of all 
PLHIV will know their HIV status; (b) 90% of all peo­
ple with diagnosed HIV infection will receive sustained 
antiretroviral therapy; and (c) 90% of people receiv­
ing antiretroviral therapy will achieve viral suppres­
sion (Global gains made towards the 90­90­90 targets 
UNAIDS, 2016)
In the present study males accounted for two 
thirds of cases. Similarly, 83% of HIV infected patients 
VL (1)
 < detection leveld   2 12.5 –
 > detection leveld 14 87.5 3396.14 ± 5227.32 
ZL = –3.18 (0.00)**
VL (2)
 < detection leveld   2 12.5 –
 > detection leveld 14 87.5 4170.29 ± 6703.13
Table III
Viral load (IU/ml) among the studied HIV­infected patients
Abbreviations:
HIV – human immune deficiency virus; VL – viral load; Z – Z value of Wilcoxon Signed Ranks test; 
** – significant at p ≤ 0.01; VL (1) – VL measured at the beginning of the study;
VL (2) – VL measured after one year of the study; d – detection level was 50 IU/ml;
& – VL (1) – VL (2) for HIV patients whose viral load was above detection level (n = 18);
L – VL (1) – VL (2) for HIV patients whose viral load was above detection level (n = 14)
VL among all HIV­infected patients (n = 20)
No. % Mean ± SD Test of significance(p value)
VL (1)
 < detection leveld  2 10 –
 > detection leveld 18 90 6990 ± 8593.65 
Z& = –2.84 (0.00)**
VL (2)
 < detection leveld  2 10 –
 > detection leveld 18 90 8010.22 ± 10193.1
VL among HIV­infected patients who received treatment (n = 4)
Min­Max Mean ± SD Test of significance(p value)
VL (1) 15400 – 27000 19570 ± 5366.40
VL (2) 12000 – 34000 21450 ± 9187.49
VL among HIV­infected patients who did not receive treatment (n = 16)
No. % Mean ± SD Test of significance(p value)
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Gender
Male 77 (85.6) 23 (38.3) X2 = 36.12 (0.00)**
Female 13 (14.4) 37 (61.7)
Age (Years) (Mean ± SD) 35 ± 9.18 32.32 ± 9.18 t = 1.76 (0.08)
Marital status
Single 41 (45.6) 19 (31.7) MC p = 0.12
Married 31 (34.4) 27 (45)
Divorced 15 (16.7) 8 (13.3)
Widowed 3 (3.3) 6 (10)
Residence
Rural 7 (7.8) 1 (1.7) FEp = 0.14
Urban 83 (92.2) 59 (98.3)
Education
Illiterate 19 (21.1) 19 (31.7) MC p = 0.00**
Read & write 12 (13.3) 10 (16.7)
Primary 6 (6.7) 10 (16.7)
Secondary 10 (11.1) 11 (18.3)
University 6 (6.7) 3 (5)
Vocational training 37 (41.1) 7 (11.7)
Family member living with HIV 42 (46.7) 41 (68.3) X2 = 6.83 (0.00)**
IV drug abuse 31 (34.4) 5 (8.3) X2 = 13.45 (0.00)**
Duration since HIV diagnosis
< 5 years 33 (36.7) 25 (41.7) X2 = –0.41 (0.81)
5 – 15 years 48 (53.3) 30 (50)
> 15 years 9 (10) 5 (8.3)
Co-morbidity< 31 (34.4) 14 (23.3) X2 = 2.11 (0.14)
Symptomatic HIV 71 (78.9) 50 (83.3) X2 = 0.45 (0.50)
Type of progression
Progressive (P) 16 (17.8) 21 (35) MC p = 0.03*
Rapidly progressive (RP)  57 (63.3) 27 (45)
Long­term non­progressive 4 (4.4) 6 (10)
Controller 13 (14.4) 6 (10)
CD4+ T cells (cells/mm3)^
< 100 7 (7.8) 8 (13.3) MCp = 0.13
100–199 3 (3.3) 6 (10)
200–349 21 (23.3) 8 (13.3)
≥ 350  59 (65.6) 38 (63.3)
Viral load (IU/ml)$ (n = 11) (n = 9) FEp = 1
< 10000 8 (72.7) 6 (66.7)
≥ 10000 3 (27.3) 3 (33.3)
Receiving cART  73 (81.1) 48 (80) X2 = 0.02 (0.86)
Table IV
Characteristics of the studied HIV­infected patients with respect to patients’ employment status (n = 150)
Abbreviations:
HIV – human immune deficiency virus; st. – status; < – diabetes mellitus, hypertension, hepatitis C virus, hepatitis B virus;
cART­combined antiretroviral therapy; ^ – baseline CD4 T­helper counts; X2 – Chi square test; FE – Fisher’s Exact test;
MC – Monte Carlo test; t – student t­test; SD – standard deviation; * – significant at p ≤ 0.05 (2­tailed);
** – significant at p ≤ 0.01 (2­tailed)
Characteristics Employed HIV patients (n = 90) Unemployed HIV patients (n = 60) Test of significance
(p value)No (%) No (%)
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reported were males with same age range in an Egyp­
tian survey (Jackobsen, 2014).
The majority of our patients had urban residence 
(94.7%) and Amrya district showed the highest clus­
tering (30.7%). Amrya district was also found to be 
the second highest district of HCV clustering in a PhD 
study conducted at the AFM (Gamaleldeen, 2016). 
Sexual transmission and drug abuse remain the 
major routes of HIV infection in MENA including 
Egypt (Gokengin et al., 2016). Our results of HIV due 
to IV abuse is in harmony with the results of a national 
surveillance study showing that 28% of reported HIV 
infected patients in Egypt in 2010 occurred in PWID 
which is consistent with an epidemic that dispropor­
tionately affects MSM and/or PWID (NAP, HIV/AIDS 
biological and behavioral surveillance; 2010). Male 
PWID comes out to 93,314; 0.37% of the male popula­
tion aged 18–59 (Jackobsen, 2014).
In the last few years, many countries in MENA 
have been affected by social and political unrest and 
conflict. However, the current HIV prevalence of 0.1% 
is still among the lowest rates globally (El Beih et al., 
2012). Iran has the highest numbers of PWID (185 000, 
0.43%), followed by Pakistan (117 000) and Egypt 
(93 000) (Mumtaz et al., 2014).
HCV is a common co­infection among PLHIV in 
Egypt. This is due to the high background of HCV prev­
alence in the general population (7%) (EHIS, 2015). 
As in most countries, Egypt is adopting nucleic acid 
testing in blood banks to provide safe blood transfu­
sions (Egyptian national standards for blood trans ­ 
fusion, 2011).
The development of signs and symptoms of AIDS 
typically parallels laboratory testing for CD4 lympho­
cytes. CD4 lymphocyte count, HIV VL and follow up 
duration are key components used to define HIV phe­
notypes (Gurdasani et al., 2014).
In our study group, RP accounted for 56% while 
average percent is around 10–15% (Gurdasani et al., 
2014). This could be attributed to that those patients 
have signs and symptoms so they are more keen to 
show up for treatment and follow up. Also, PLHIV is 
Gender
Female^   – – –  –
Male  1.98 7.29 2.72–19.52 0.00**
Education
Illiterate^   – – –  –
Read and write  0.60 1.82 0.50–6.58 0.35
Primary –0.19 0.82 0.20–3.33 0.78
Secondary  0.07 1.07 0.30–3.85 0.91
University   0.94 2.57 0.42–15.57 0.30
Vocational training  1.79 6.04 1.81–20.16 0.00**
Having family member living with HIV
Yes  0.16 1.17 0.45–3.07 0.74
No^  – – –  –
IV drug abuse
Yes  0.93 2.54 0.78–8.28 0.12
No^  – – –  –
Disease progression
Progressive –1.23 0.29 0.06–1.22 0.09
Rapidly progressive –0.515 0.59 0.16–2.22 0.44
LTNP –1.09 0.33 0.04–2.39 0.27
Controller^   – – –  –
Model X2 = 57.11 (0.00)**
Table V
Predictors of employment in the studied HIV­infected patients (n = 150)a
Abbreviations:
HIV – human immune deficiency virus; LTNP – long term non­progressive; IV – intravenous;
a – Multivariate odds ratios using logistic regression; ^ – Reference;
# – Odds ratios adjusted for all variables listed in the table; X2 – Chi square; ** – significant at p ≤ 0.001
Characteristics
Multivariate analysis (logistic regression)
β p value95%CIOR#
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still a stigma as described in the Egyptian society for 
population studies (Stigma experienced by people liv­
ing with HIV in Egypt, 2013).
In the current study, LTNP accounted for 6.7% 
which is similar to average estimates (5–10%) (Gur­
dasani et al., 2014). EC proportion varies greatly 
between studies, it ranged from 0.15–7.70% according 
to the Concerted Action on SeroConversion on AIDS 
and Death in Europe (CASCADE) dataset as it did 
not necessarily reflect the length of follow­up required 
by the definition.
The best laboratory measure for determination of 
the long term progression of AIDS for therapeutic 
purposes is the level of HIV RNA in peripheral blood. 
Despite ART, the reconstitution of the immune system 
may be partial or incomplete, with considerable varia­
bility in the magnitude of the response (Gunthard et al., 
2016). CD4 count response is controversial, it mostly 
increases but still may remain below normal.
In our study, the significantly higher CD4+(4) 
count among the whole cohort and among the treated 
group as well as significantly higher VL (2) among 
the untreated group intensify the importance for ART 
in HIV patients.
CCR5 is a prominent cofactor for HIV­1 entry. 
74 mutations including the intensively studied 32 base 
pair deletion (CCR5­delta32) were identified. We 
detected no deletion mutations among selected LTNP 
cases. Mutation occurs most frequently in the Cauca­
sian population, while it cannot be found in the Asian, 
Middle East, African, and the American Indian popula­
tion (Gero et al., 2011).
In the present study, the unemployment rate among 
HIV­infected patients was 40%. The result coincides 
with unemployment rates of 45–65% reported by Dray­
Spira et al. (2007) and 40% reported by Rabkin et al. 
(2004). However, it is much higher than unemployment 
rate; 12.1%, among HIV­infected patients reported in 
Gros et al (2016) which could be attributed to national 
difference; the overall unemployment rate in Rabkin 
et al. (2004) in Germany (4.6%) is lower than that in 
Egypt according to ILO, 2016 (12.7%). Yet, results of the 
current research are consistent with recent studies that 
indicates higher unemployment rates of HIV­infected 
individuals compared with the background population.
On studying predictors of employment for HIV­
infected patients, HIV­infected men were more likely to 
be employed than HIV­infected women. Likewise, Dray 
Spira et al. (2007), reported lower rates of employment 
among HIV­infected women (46.9%) compared with 
HIV­infected men (65.1%), however, in the current 
study, employment rate among women was very much 
lower than Dray Spira et al., 2007 (14.4% vs 46.9%). This 
could be partially due to the fact that women, even in 
absence of HIV disease, have lower opportunity regard­
ing labor market participation especially in developing 
countries. In the general population in Egypt, unem­
ployment among females is 25.7%, compared with 8.9% 
in males (CAPMAS, 2016).
Furthermore, in the present research, HIV­infected 
patients who obtained vocational training were more 
likely to be employed compared with illiterate HIV­
infected patients. Similarly, previous studies showed 
higher probability of labor market participation in 
highly educated HIV­infected individuals as described 
by Elzi (2016) and that poor education is significantly 
associated with higher unemployment rate among HIV­
infected patients (Gros et al., 2016).
According to HIV/AIDS Strategic Frame 2012–
2016; Egypt’s goal is to stabilize the growth of the AIDS 
epidemic in the country, prevent new infections espe­
cially within the most at risk population and improve 
health outcomes for PLHIV. National positive response 
developments; most notably prevention programmes 
for the key populations of PWID and MSM, have been 
implemented. HIV testing is available for diagnostic 
purposes and both governmental and nongovernmental 
voluntary testing and counselling are being expanded. 
Treatment centers have been set up at fever hospitals. 
Stigma and discrimination are prohibited and various 
care and supportive measures are undertaken.
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